Stock Events

Cognetivity Neurosciences 

$0
2
+$0+0% Thursday 20:00

Statistics

Day High
0
Day Low
0
52W High
0.14
52W Low
0
Volume
10,000
Avg. Volume
25,587
Mkt Cap
686,874
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

16DecExpected
Q3 2020
Q1 2021
Q2 2021
Q3 2021
Q1 2022
Q2 2022
Q3 2022
-0.08
-0.06
-0.03
-0.01
Expected EPS
N/A
Actual EPS
-0.017

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CGNSF. It's not an investment recommendation.
Alphabet
72554
GOOGL
Apple
63389
AAPL
Microsoft
59081
MSFT
Amazon
54705
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Lilly(Eli) &
LLY
Mkt Cap864.43B
Eli Lilly is a major pharmaceutical company that develops drugs for neurological diseases, including Alzheimer's, which competes with CGNSF's cognitive assessment technologies.
Biogen
BIIB
Mkt Cap29.83B
Biogen focuses on neurodegenerative diseases, including Alzheimer's disease treatments and diagnostics, directly competing with CGNSF's cognitive testing products.
Pfizer
PFE
Mkt Cap164.39B
Pfizer develops medications for various neurological conditions, which can be seen as alternatives to CGNSF's cognitive assessment tools.
Merck
MRK
Mkt Cap300.25B
Merck is involved in the development of treatments for Alzheimer's disease, competing in the same space as CGNSF's cognitive diagnostics.
Abbott Laboratories
ABT
Mkt Cap197.08B
Abbott Laboratories offers a range of healthcare solutions including diagnostics for neurological conditions, overlapping with CGNSF's market.
Sage Therapeutics
SAGE
Mkt Cap514.65M
Sage Therapeutics develops treatments for central nervous system disorders, which can be used alongside or as an alternative to CGNSF's technologies.
Novartis
NVS
Mkt Cap244.75B
Novartis provides healthcare solutions including neurological disease treatments, competing in the cognitive health space.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson, through its pharmaceutical division, develops treatments for neurodegenerative diseases, competing with CGNSF's cognitive assessment tools.
AC Immune SA
ACIU
Mkt Cap319.58M
AC Immune focuses on Alzheimer's disease diagnostics and therapeutics, directly competing with CGNSF's cognitive assessment technologies.

About

Biotechnology
Health Technology
Cognetivity Neurosciences Ltd. operates as a healthcare company. It develops an integrated cognitive assessment, a cognitive testing platform for use in medical, commercial, and consumer environments that helps to detect the earliest signs of impairment by testing the performance of large areas of the brain to support the diagnosis of dementia; and offers OptiMind, a wellness app. The company was formerly known as Utor Capital Corp. and changed its name to Cognetivity Neurosciences Ltd. in December 2017. Cognetivity Neurosciences Ltd. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Show more...
CEO
Employees
2500
Country
CA
ISIN
CA19243C1005

Listings

CN
CA
CGN.CN
US
CGNSF
F
DE
1UB.F